UNSPSC 51373427: Chlorpheniramine/codeine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373427 Chlorpheniramine/codeine/pseudoephedrine is a Commodity code under which state and local governments procure pharmaceutical products, including over-the-counter medications, generic multi-source pharmaceuticals, and naloxone-based emergency medical supplies. The code captures procurement activity spanning county health departments, state purchasing alliances, and cooperative purchasing organizations that distribute pharmaceuticals to public facilities and community health programs. Issuing bodies include county health systems and state-level cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and member entities.

Recent activity shows procurement concentrated in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, supported by potential FEMA funding. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, responses due March 26, 2026) seeking multiple awards for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) to participating state and local government facilities across Minnesota and Oregon. MMCAP's evaluation weights price competitiveness at 75 percent, with contract terms of two years for new responders, optional extensions for incumbents through June 30, 2028, and a 3 percent administrative fee on all purchases. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence.